Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancies and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-3 Recombinant Protein High purity (>95%), Endotoxin controlled (<1 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View IL3 Products |
| Gene Delivery | IL-3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View IL3 Products |
| Benchmark Ab | Anti-IL-3 Recombinant Antibody High-affinity positive control for neutralization and ELISA assays. |
View IL3 Products |
| Validator | IL-3 siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View IL3 Products |
| Related Target A | CD123 (IL-3RA) The primary alpha subunit of the IL-3 receptor, critical for high-affinity IL-3 binding and therapeutic targeting (e.g., ADCs, CAR-T, Bispecifics). |
View CD123 Products |
| Related Target B | CSF2RB (IL-3RB) The common beta subunit shared among IL-3, IL-5, and GM-CSF receptors, vital for signal transduction. |
View CSF2RB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species Cross-Reactivity Assessment | Human and Cynomolgus ortholog proteins available with >95% purity to confirm species-spanning binding kinetics. |
| Receptor Interaction & Binding Kinetics | High-purity CD123 (IL-3RA) and CSF2RB extracellular domains (ECD) available for precise SPR/BLI affinity determination. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay standardization. |
| Off-Target Screening and False Positives | Sequence-verified siRNA sets and negative controls provided for target validation. |
Live IL-3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the IL-3/CD123 axis has emerged as a major focus in hematological oncology, particularly in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and Acute Myeloid Leukemia (AML). While early-generation therapies focused on IL-3-toxin fusions (e.g., Tagraxofusp), the field is rapidly shifting toward sophisticated modalities, including CD123-targeted antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR-T cell therapies.
The next wave of R&D is highly focused on mitigating safety risks, such as capillary leak syndrome (CLS), by engineering therapies with optimized binding kinetics and pH-dependent release profiles. Additionally, modulating the IL-3 pathway in autoimmune diseases and chronic inflammation represents an expanding frontier beyond oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Fusion Toxins | Stemline Therapeutics (Menarini) | BPDCN, AML, Myelofibrosis | Receptor binding assays (Requires high-purity CD123 and CSF2RB proteins) |
| Antibody-Drug Conjugates (ADCs) | ImmunoGen, AbbVie | Acute Myeloid Leukemia (AML) | Internalization validation (Requires stable CD123-expressing target cell lines) |
| Bispecific Antibodies / T-Cell Engagers | MacroGenics, Janssen | Relapsed/Refractory AML, MDS | Dual-target binding assays (Requires cross-reactive human/cyno CD123 and CD3 proteins) |
| Monoclonal Antibodies (mAbs) | CSL Behring | Inflammatory Diseases, Leukemia | Neutralization and ligand-blocking assays (Requires highly active recombinant IL-3 ligand) |